IP Library › Granted Patent US 7,435,801
Granted Patent B2
US 7,435,801 · App. 10/420,067 · Granted Oct 14, 2008

Antibodies and other ligands directed against KIR2DL4 receptor for production of interferon gamma

Assignee: The United States of America, as represented by the Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,801
App. No.
10/420,067
Granted
Oct 14, 2008
Kind
B2
Abstract

The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.

Claims (17)

1. A monoclonal antibody, mAb #33, produced by the hybridoma cell line having Accession No. ATCC PTA-2594.

2. A chimeric version of a monoclonal antibody, mAb #33, produced by the hybridoma cell line having Accession No. ATCC PTA-2594.

3. A humanized version of a monoclonal antibody, mAb #33, produced by the hybridoma cell line having Accession No. ATCC PTA-2594.

4. A Fab fragment of a monoclonal antibody, mAb #33, produced by the hybridoma cell line having Accession No. ATCC PTA-2594.

5. A F(ab′)2 fragment of a monoclonal antibody, mAb #33, produced by the hybridoma cell line having Accession No. ATCC PTA-2594.

6. A hybridoma cell line having ATCC Accession No. PTA-2594.

7. A composition comprising the monoclonal antibody of claim 1 or a fragment or single chain antibody thereof that specifically binds to human KIR2DL4 receptor and stimulates production of interferon gamma.

8. A pharmaceutical composition comprising the monoclonal antibody of claim 1 or a fragment or single chain antibody thereof that specifically binds to human KIR2DL4 receptor and stimulates production of interferon gamma, and a pharmaceutically acceptable carrier.

9. The composition of claim 7 or 8 , wherein said composition comprises said monoclonal antibody or said fragment.

10. The composition of claim 7 or 8 , wherein said composition comprises said monoclonal antibody.

11. The composition of claim 7 or 8 , wherein said composition comprises said single chain antibody.

12. A composition comprising the antibody of claim 2 or 3 that specifically binds to human KIR2DL4 receptor and stimulates production of interferon gamma.

13. The composition of claim 12 , wherein said composition comprises said chimeric antibody.

14. The composition of claim 12 , wherein said composition comprises said humanized antibody.

15. A pharmaceutical composition comprising the antibody of claim 2 or 3 that specifically binds to human KIR2DL4 receptor and stimulates production of interferon gamma, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 , wherein said composition comprises said chimeric antibody.

17. The pharmaceutical composition of claim 15 , wherein said composition comprises said humanized antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2003
From: LONG, ERIC O.; RAJAGOPALAN, SUMATI
To: HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE
Reel/Frame 014441/0717 →
Continuity (3)
Continuation PCTUS014609800 · Oct 23, 2001
Provisional Application 6024241900 · Oct 23, 2000
Related Publication 20030232051A1 · Dec 18, 2003